

# Junning Cao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3902379/publications.pdf>

Version: 2024-02-01

29  
papers

336  
citations

1307594

7  
h-index

839539

18  
g-index

29  
all docs

29  
docs citations

29  
times ranked

577  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 7363-7369.	7.0	102
2	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 22.	17.0	50
3	A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 259-269.	2.3	45
4	A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2014, 7, 22.	17.0	29
5	Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. <i>Oncotarget</i> , 2016, 7, 32519-32531.	1.8	14
6	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1897-1908.	4.2	12
7	Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended follow-up of the multicenter, single-arm, phase 2 study. <i>International Journal of Cancer</i> , 2021, , .	5.1	11
8	Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 616-626.	2.2	10
9	A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. <i>Hematology</i> , 2017, 22, 258-264.	1.5	8
10	Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma. <i>Annals of Nuclear Medicine</i> , 2021, 35, 834-842.	2.2	8
11	PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR. <i>Molecular Medicine Reports</i> , 2020, 21, 2209-2219.	2.4	7
12	Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIIE, extranodal NK/T-cell lymphoma patients. <i>Cancer Medicine</i> , 2020, 9, 5400-5405.	2.8	6
13	Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. <i>Oncotarget</i> , 2016, 7, 33331-33339.	1.8	6
14	The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance. <i>Aging</i> , 2021, 13, 181-193.	3.1	6
15	Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 145-151.	2.0	4
16	Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	1.3	4
17	Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2017, 22, 638-e56.	3.7	3
18	<p><p>Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma<p><p>Cancer Management and Research, 2020, Volume 12, 5041-5048.	1.9	3

#	ARTICLE	IF	CITATIONS
19	Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1178-1178.	1.7	3
20	Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy. <i>Leukemia Research</i> , 2018, 74, 80-85.	0.8	2
21	Epirubicin Does Not Lower The Risk Of Cardiac Toxicity Than Doxorubicin In Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma Grade 3 (FLG3): Results From a 398-Case Prospective Randomized Phase III Clinical Trial (NCT00854568). <i>Blood</i> , 2013, 122, 372-372.	1.4	1
22	Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas. <i>Blood</i> , 2020, 136, 38-38.	1.4	1
23	Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. <i>BMC Cancer</i> , 2022, 22, 403.	2.6	1
24	Interim PET/CT result is the sole prognostic factor of survival in patients with advanced-stage diffuse large B-cell lymphoma: a subset analysis of a prospective trial. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2021, 327, 353-358.	1.5	0
25	Re-Assessment of the Prognostic Value of International Prognostic Index (IPI) and Revised IPI (R-IPI) in Patients with Diffuse Large B-Cell Lymphoma Treated with or without Rituximab in Chinese Populations: A Retrospective Multicenter Study by Shanghai Lymphoma Research Group. <i>Blood</i> , 2011, 118, 2649-2649.	1.4	0
26	A phase I dose escalation study of hPV19, a novel humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in patients with advanced solid tumors refractory to standard therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2522-2522.	1.6	0
27	Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post-the Incorporation of Rituximab to Standard CHOP Chemotherapy. <i>Blood</i> , 2019, 134, 5233-5233.	1.4	0
28	Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4542-4542.	1.4	0
29	Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 14-15.	1.4	0